First Header Logo Second Header Logo

Connection

Jason Powell to Humans

This is a "connection" page, showing publications Jason Powell has written about Humans.
Connection Strength

0.198
  1. Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, Moretti PA, Iarossi D, Samaraweera SE, Cummings N, Ramshaw HS, Thomas D, Wei AH, Lopez AF, D'Andrea RJ, Lewis ID, Pitson SM. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017 02 09; 129(6):771-782.
    View in: PubMed
    Score: 0.033
  2. Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'Andrea RJ, Lopez AF, Guthridge MA. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 2009 Nov 26; 114(23):4859-70.
    View in: PubMed
    Score: 0.020
  3. Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics. 2002 Sep; 80(3):303-10.
    View in: PubMed
    Score: 0.012
  4. Matthews GS, Kiani B, Wuertzer SD, Powell JA, Roller BL, Lenchik L, Torabi M. MRI of the Wrist: Algorithmic Approach for Evaluating Wrist Pain. Radiographics. 2019 Mar-Apr; 39(2):447-448.
    View in: PubMed
    Score: 0.010
  5. Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM. Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene. 2019 02; 38(8):1151-1165.
    View in: PubMed
    Score: 0.009
  6. Wallington-Beddoe CT, Xie V, Tong D, Powell JA, Lewis AC, Davies L, Pitson SM, Bradstock KF, Bendall LJ. Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2019 02; 184(3):443-447.
    View in: PubMed
    Score: 0.009
  7. Giffen MA, Powell JA, McLemore J. Forensic Radiology Pitfalls: CT Imaging in Gunshot Wounds of the Head. J Forensic Sci. 2018 Mar; 63(2):631-634.
    View in: PubMed
    Score: 0.009
  8. Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood. 2017 05 25; 129(21):2882-2895.
    View in: PubMed
    Score: 0.008
  9. Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, Chan H, Powell JA, Pitman MR, Samuel MS, Bonder CS, Creek DJ, Gliddon BL, Pitson SM. An oncogenic role for sphingosine kinase 2. Oncotarget. 2016 Oct 04; 7(40):64886-64899.
    View in: PubMed
    Score: 0.008
  10. Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget. 2016 Jul 26; 7(30):47465-47478.
    View in: PubMed
    Score: 0.008
  11. Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul; 100(7):914-26.
    View in: PubMed
    Score: 0.007
  12. Pitman MR, Powell JA, Coolen C, Moretti PA, Zebol JR, Pham DH, Finnie JW, Don AS, Ebert LM, Bonder CS, Gliddon BL, Pitson SM. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget. 2015 Mar 30; 6(9):7065-83.
    View in: PubMed
    Score: 0.007
  13. Wallington-Beddoe CT, Powell JA, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res. 2014 May 15; 74(10):2803-15.
    View in: PubMed
    Score: 0.007
  14. Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, RĂ©cher C, Wei AH, Guthridge MA. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood. 2013 Aug 01; 122(5):738-48.
    View in: PubMed
    Score: 0.006
  15. Lonic A, Powell JA, Kong Y, Thomas D, Holien JK, Truong N, Parker MW, Guthridge MA. Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. J Biol Chem. 2013 May 24; 288(21):14874-85.
    View in: PubMed
    Score: 0.006
  16. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biol. 2013; 11(3):e1001515.
    View in: PubMed
    Score: 0.006
  17. Pitson SM, Powell JA, Bonder CS. Regulation of sphingosine kinase in hematological malignancies and other cancers. Anticancer Agents Med Chem. 2011 Nov; 11(9):799-809.
    View in: PubMed
    Score: 0.006
  18. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 2010 Jul 01; 70(13):5438-47.
    View in: PubMed
    Score: 0.005
  19. Barry EF, Felquer FA, Powell JA, Biggs L, Stomski FC, Urbani A, Ramshaw H, Hoffmann P, Wilce MC, Grimbaldeston MA, Lopez AF, Guthridge MA. 14-3-3:Shc scaffolds integrate phosphoserine and phosphotyrosine signaling to regulate phosphatidylinositol 3-kinase activation and cell survival. J Biol Chem. 2009 May 01; 284(18):12080-90.
    View in: PubMed
    Score: 0.005
  20. Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008 Nov 01; 121(Pt 21):3541-52.
    View in: PubMed
    Score: 0.005
  21. Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To B, Begley CG, Lopez AF. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J. 2006 Feb 08; 25(3):479-89.
    View in: PubMed
    Score: 0.004
  22. Kumar R, Neilsen PM, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen AM, Callen DF. FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res. 2005 Dec 15; 65(24):11304-13.
    View in: PubMed
    Score: 0.004
  23. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen AM, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G, Sutherland GR, Callen DF. CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res. 2002 Aug 15; 62(16):4599-604.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.